Orphazyme and Rotterdam Biologics are due to appear before the European Medicines Agency this week to explain why their respective investigational drugs – arimoclomol and Ipique (bevacizumab) – should be approved for marketing in the EU.
Both companies have previously experienced key regulatory setbacks for their products – Orphazyme in the US and Rotterdam Biologics in...








